Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-21

Study Completion Date

2023-10-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05061719

Major Depressive Disorder

COMPLETED PHASE3

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

NCT00531947

Major Depressive Disorder

COMPLETED PHASE4

Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder

NCT01733654

Depression Major Depressive Disorder

WITHDRAWN PHASE2

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436149

Major Depressive Disorder

COMPLETED PHASE3

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

NCT01288079

Major Depressive Disorder

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed to compare the safety, pharmacokinetics, and efficacy of weekly and daily formulations of setmelanotide in participants with obesity associated with biallelic or heterozygous POMC (pro-opiomelanocortin), PCSK1 (proprotein convertase subtilisin/kexin Type 1), LEPR (leptin receptor) genetic variants, and participants with Bardet-Biedl Syndrome (BBS).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bardet-Biedl Syndrome POMC Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Run-in Period: Setmelanotide 2 mg QD

Participants received subcutaneous (SC) injection of 2 mg setmelanotide once daily (QD) for 1 week in the run-in period.

Group Type EXPERIMENTAL

Setmelanotide 2 mg

Intervention Type DRUG

Administered as SC injection

Run-in Period: Setmelanotide 2.5 mg QD

Participants received SC injection of 2.5 mg setmelanotide QD for 1 week in the run-in period.

Group Type EXPERIMENTAL

Setmelanotide 2.5 mg

Intervention Type DRUG

Administered as SC injection

Run-in Period: Setmelanotide 3 mg QD

Participants received SC injection of 3 mg setmelanotide QD for 1 week in the run-in period.

Group Type EXPERIMENTAL

Setmelanotide 3 mg

Intervention Type DRUG

Administered as SC injection

DB Period: Setmelanotide 20 mg QW

Participants who received 2 mg setmelanotide QD in the run-in period, received SC injection of 20 mg setmelanotide once weekly (QW) and placebo matched to setmelanotide QD for 13 weeks in the DB period.

Group Type EXPERIMENTAL

Setmelanotide 20 mg

Intervention Type DRUG

Administered as SC injection

DB Period: Setmelanotide 25 mg QW

Participants who received 2.5 mg setmelanotide QD in the run-in period, received SC injection of 25 mg setmelanotide QW and placebo matched to setmelanotide QD for 13 weeks in the DB period.

Group Type EXPERIMENTAL

Setmelanotide 25 mg

Intervention Type DRUG

Administered as SC injection

DB Period: Setmelanotide 3 mg QD

Participants who received 3 mg setmelanotide QD in the run-in period, received SC injection of 3 mg setmelanotide QD and placebo matched to setmelanotide QW for 13 weeks in the DB period.

Group Type EXPERIMENTAL

Setmelanotide 3 mg

Intervention Type DRUG

Administered as SC injection

DB Period: Setmelanotide 30 mg QW

Participants who received 3 mg setmelanotide QD in the run-in period, received SC injection of 30 mg setmelanotide QW and placebo matched to setmelanotide QD for 13 weeks in the DB period.

Group Type EXPERIMENTAL

Setmelanotide 30 mg

Intervention Type DRUG

Administered as SC injection

OL Period: Setmelanotide 20 mg QW

Participants who received 2 mg setmelanotide QD in the run-in period and 20 mg setmelanotide QW in the DB period, received SC injection of 20 mg setmelanotide QW for 13 weeks in the OL period.

Group Type EXPERIMENTAL

Setmelanotide 20 mg

Intervention Type DRUG

Administered as SC injection

OL Period: Setmelanotide 25 mg QW

Participants who received 2.5 mg setmelanotide QD in the run-in period and 25 mg setmelanotide QW in the DB period, received SC injection of 25 mg setmelanotide QW for 13 weeks in the OL period.

Group Type EXPERIMENTAL

Setmelanotide 25 mg

Intervention Type DRUG

Administered as SC injection

OL Period: Setmelanotide 30 mg QW

Participants who received 3 setmelanotide QD in the run-in period and 3 mg setmelanotide QD or 30 mg setmelanotide QW in the DB period, received SC injection of 30 mg setmelanotide QW for 13 weeks in the OL period.

Group Type EXPERIMENTAL

Setmelanotide 30 mg

Intervention Type DRUG

Administered as SC injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Setmelanotide 2 mg

Administered as SC injection

Intervention Type DRUG

Setmelanotide 2.5 mg

Administered as SC injection

Intervention Type DRUG

Setmelanotide 3 mg

Administered as SC injection

Intervention Type DRUG

Setmelanotide 20 mg

Administered as SC injection

Intervention Type DRUG

Setmelanotide 25 mg

Administered as SC injection

Intervention Type DRUG

Setmelanotide 30 mg

Administered as SC injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Biallelic or heterozygous POMC/PCSK1 or LEPR (PPL) genetic variants or Bardet-Biedl syndrome (BBS), for which they are being treated with QD setmelanotide.
* 6 years or older at screening.
* Taking the setmelanotide QD formulation for at least 6 months in the RM-493-022 (NCT03013543) study with acceptable safety and tolerability, and dose level.
* Participant and/or parent or guardian is able to communicate well with the Investigator, to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent.
* Use of a highly effective form of contraception throughout the study and for 90 days following the study.

Exclusion Criteria

* Glycosylated hemoglobin (HbA1C) \>9.0% at screening.
* Anti-obesity medications within 3 months prior to starting the Run-in Period.
* History of significant liver disease or liver injury.
* Glomerular filtration rate \<30 milliliter per minute (mL/min).
* Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions.
* Major psychiatric disorders.
* Any suicidal ideation or behavior, or any lifetime history of a suicide attempt.
* Significant hypersensitivity to any excipient in the study drug.
* Inability to comply with the QW and QD injection regimens.
* Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing, with the exception of a setmelanotide clinical trial.

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No